Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Tracon Pharmaceuticals Inc.
Study ID
NCT03835949
Phase
PHASE1
Status
Unknown

Conditions

  • Metastatic Cancer
  • Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TJ004309 — DRUG
    Antibody to CD73
  • Atezolizumab — DRUG
    Humanized monoclonal antibody to PD-L1

Study Details

This is a multicenter, open label, Phase 1 dose escalation study of TJ004309 in combination with standard dose atezolizumab in patients with advanced or metastatic cancer in patients who are refractory to or intolerant to all available therapy.

Key Dates

Start date
Jul 16, 2019
Status verified
Mar 2022
Primary completion
Jun 30, 2022
Completion
Jun 30, 2022

Study Design

Enrollment
36 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: TJ004309 plus Atezolizumab
    TJ004309 will be dose escalated in a 3+3 design in combination with atezolizumab.

Primary Outcome Measure

Maximum Tolerate Dose of TJ004309 plus Atezolizumab [ Time Frame: Approximately 2-8 months ]

Locations (4)

FacilityCityStateZIPSite coordinators
The University of Alabama at BirminghamBirminghamAlabama35294-
HonorHealth Research InstituteScottsdaleArizona85258-
City of HopeDuarteCalifornia91010-
MD Anderson Cancer CenterHoustonTexas77230-

Find similar trials in Birmingham, AL

By research site
The University of Alabama at Birmingham· Birmingham, ALHonorHealth Research Institute· Scottsdale, AZCity of Hope· Duarte, CAMD Anderson Cancer Center· Houston, TX

Related Studies